Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

Alimuddin Zumla, Martin Rao, Robert S Wallis, Stefan H E Kaufmann, Roxana Rustomjee, Peter Mwaba, Cris Vilaplana, Dorothy Yeboah-Manu, Jeremiah Chakaya, Giuseppe Ippolito, Esam Azhar, Michael Hoelscher, Markus Maeurer, for the Host-Directed Therapies Network consortium

Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen-host interactions, pathogenesis, inflammatory pathways, and the host’s innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient’s own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.

Introduction

Infectious diseases are leading causes of morbidity and mortality worldwide.1 In high-income countries, mortality from respiratory tract infections remains high despite access to quality health services and availability of antibiotic therapy.1 The intermittent emergence of new zoonotic pathogens and the increasing incidence of treatment-resistant infections draws attention to the limits of the current antimicrobial treatment portfolio and the urgent need for alternative management strategies.

In evolutionary terms, host–pathogen interactions are dependent on the microbe surviving without causing harm to the host. The host’s innate and adaptive immune surveillance mechanisms govern whether the infection will be contained or progress to clinical disease with either recovery or death. Several host factors affect antimicrobial treatment outcome and are responsible for progression of disease after infection, poor treatment response, tissue damage, long-term functional disability, and increased mortality. These factors include immune dysregulation from any cause (aberrant or excess host inflammatory response to infection, stress, immunosuppressive drugs, poor living conditions, socioeconomic factors, micronutrient deficiencies, HIV, malnutrition, and alcohol or substance misuse) and comorbidity with non-communicable diseases such as diabetes, cancer, smoking, and chronic obstructive pulmonary disease.1

During the past 4 years, a renaissance of scientific research strategies targeting host factors—rather than pathogen components directly—is leading to development of a wide range of host-directed therapies that target and modify biological pathways to achieve a positive clinical treatment outcome.

Key messages

- Despite the availability of antimicrobial drugs, infectious diseases are leading causes of morbidity and mortality worldwide.
- The widespread emergence of antimicrobial resistance calls for novel interventions in addition to new antimicrobial development.
- A range of host factors are responsible for development of disease, poor treatment response, and increased mortality. These include immune dysregulation from any cause and comorbidity with non-communicable diseases such as diabetes, cancer, smoking, and chronic obstructive pulmonary disease.
- During the past 4 years, a renaissance of scientific research strategies targeting host factors—rather than pathogen components directly—is leading to development of a wide range of host-directed therapies that target and modify biological pathways to achieve a positive clinical treatment outcome.
- Host-directed therapies can augment host cellular responses to pathogens, target disease-causing virulence factors, activate innate and adaptive protective immune responses, or modulate excessive inflammation, leading to reduced morbidity, mortality, and end-organ damage.
- The broad spectrum efficacy of host-directed therapies could also be useful for treatment of infectious diseases with epidemic potential, which are associated with high mortality.
- Host-directed therapies have the additional unique benefit of preventing or reducing the development of antibiotic resistance.
Examples of host-directed therapies include commonly used and affordable drugs for non-communicable diseases with good safety profiles; immunomodulatory agents, biologics, nutritional products, and cellular therapy using the patient’s own immune or mesenchymal stromals cells (table 1). See appendix for discussion of potential host factors for targets of host-directed therapy against infectious disease.

Studies of host-directed therapies also enable new insights into underlying mechanisms of pathogenesis, inflammatory pathways, and the host’s innate and acquired immune responses. In this Review we discuss clinically relevant examples of progress in identification of candidate host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.

**Bacterial infections**

Tuberculosis is the most common cause of death from an infectious disease worldwide.89 Since the declaration of tuberculosis as a global emergency in 1993 by WHO, there has been a major focus on development of new drugs that target *Mycobacterium tuberculosis*, the causative pathogen. For decades, the notion that *M tuberculosis* is largely intracellular in nature, and intact T-cell responses (T-helper-1 [Th1] CD4 cytotoxic lymphocytes, CD8 cytotoxic lymphocytes, and natural killer T cells) and interferon-γ production are needed to restrict *M tuberculosis* growth.90 Pulmonary tissue pathology, substantial tissue destruction, and subdued protective anti- *M tuberculosis* immune responses are noted in patients with tuberculosis who are predominantly affected by tumour necrosis factor (TNF)-α-mediated inflammation.89

Improving treatment for both drug-sensitive and MDR tuberculosis is a high priority. Few new anti-*M tuberculosis* drugs are in clinical assessment and some have substantial safety concerns. Furthermore, resistance is...
likely to develop against new tuberculosis drugs. The greatest clinical needs for tuberculosis treatment are interventions that could reduce the lengthy duration of tuberculosis therapy (currently 6 months in patients with drug-sensitive tuberculosis and 18–24 months in patients with MDR or XDR tuberculosis), thus improving patient compliance and reducing long-term toxicity; invigorate immune responses to eradicate or contain \textit{M tuberculosis}; dampen excessive inflammation and repair tissue damage to prevent long-term pulmonary damage and functional disability; and reduce the high mortality from MDR and XDR tuberculosis.

There is an expanding portfolio of host-directed therapies for use as adjunct treatments to tuberculosis therapy for improving treatment outcomes, shortening the duration of therapy, and reducing lung pathology and long-term functional disability for drug-sensitive and drug-resistant tuberculosis (table 2).136 Other host-directed therapies may decrease local inflammatory tissue pathology, including that caused by tuberculosis-associated immune reconstitution inflammatory syndrome. Examples of host-directed therapies currently being developed are cellular therapy using the patient’s own bone marrow-derived mesenchymal stromal cells,133 repurposing commonly used drugs for diabetes, epilepsy, peptic ulcers, hypercholesterolaemia, asthma, cancer, and arthritis; micronutrients and other immune-modulators; antimicrobial peptide inducers and checkpoint inhibitors; specific immune-based therapies; and therapeutic vaccines. Multinational consortia have been established to take these therapies forward in controlled clinical trials.

\textit{Streptococcus pneumoniae} is a Gram-positive bacterium that remains a major cause of childhood and adult morbidity and mortality worldwide,134 despite the availability of effective antibiotic therapy. It is largely associated with community-acquired pneumonia, and often causes invasive pneumococcal disease, affecting any organ in the body.135 Both cell-mediated and humoral immune responses operate in preventing disease in human beings.136 The pathogenesis of pneumonia is associated with overt inflammatory responses that eventually cause lung damage and death.137 Thus, several adjunctive host-directed interventions are being investigated.

The use of corticosteroids in pneumonia remains controversial, and data to support the use of corticosteroids in cases of community-acquired pneumonia are limited. In a prospective randomised clinical study of 785 patients with pneumonia in the community, prednisolone led to overall improved survival after treatment, concomitant with slightly shorter hospital stay and reduced need for mechanical ventilators, compared with placebo.138 Corticosteroids can also prevent hearing loss and other neurosensory sequelae in bacterial meningitis.139

Although the clinical use of macrolide antibiotics specifically targets the causative bacteria, macrolides might have an additional host-directed effect in treating community-acquired pneumonia. Preclinical assessment of azithromycin in mice after secondary \textit{S pneumoniae} infection following primary exposure to influenza A virus potentiated anti-inflammatory effects marked by reduction in neutrophil influx, and promoted dampening of immunopathological outcome in the lungs.139 Retrospective and prospective studies140–148 have shown that macrolide-containing antibiotic regimens decrease mortality in patients with community-acquired pneumonia, although other studies149–151 have shown no significant benefit from these regimens. Addition of a macrolide to a fluoroquinolone seems to provide some improvement in

Figure 2: Host-directed therapies as a means to counteract antimicrobial resistance
Pathogens develop resistance to antimicrobial therapy via various factors, including modification of cell-surface proteins and intracellular enzymes (bacteria and parasites), modification of envelope proteins (viruses), secretion of toxins (bacteria and parasites), sporulation and dormancy (bacteria, viruses, and fungi), activation of efflux pumps (bacteria, fungi, and parasites), and decreased permeability of cell wall (bacteria and fungi). These virulence factors impede cellular functions (solid blockade), which are required to successfully eradicate the pathogen. Host-directed therapies can counter these mechanisms by targeting impaired intracellular processes in affected host cells (blue arrow), by mechanisms such as activation of autophagy and apoptosis, induction of oxidative and nitrosative stress, and increased antigen processing and presentation, which in turn trigger necessary adaptive immune responses. Novel host-directed therapeutic strategies target host surface receptors, such as programmed death-ligand 1 (PD-L1; involved in immune exhaustion) and sialic acid-containing receptor (SAR; enhances entry of pathogens into host cells). Histone modification is done by targeting genes involved in pathogen replication and induction of apoptosis, autophagy, and antigen processing and presentation. Fatty-acid metabolism might have a role in maintenance of memory CD8 cytotoxic T-lymphocyte pools in the host. Responses induced by host-directed therapies might counteract microbial virulence factors (dotted blockade), in addition to neutralising tissue damage.
survival, suggesting a host-directed effect. Analyses in patients with community-acquired pneumonia with bacteraemia of all causes or community-acquired pneumonia with severe sepsis showed that benefit specific to macrolides was not only restricted to pneumococcal bacteraemia but was also shown for Gram-negative bacterial infections. Findings suggest that macrolides provide benefit mainly to patients with more severe illness.

The use of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of pneumonia in people has yielded conflicting results. A study investigating the
effects of ibuprofen in patients with sepsis (50% had pneumonia) showed some improvement in gas exchange, albeit without any effect on mortality. Statins (3-hydroxyl-3-methyl-glutaryl-CoA reductase inhibitors) might have a role as adjunct treatment of community-acquired pneumonia via their pleiotropic anti-inflammatory, anti-oxidative, and immunomodulatory effects; however, their effects need to be defined in randomised controlled trials. Observational studies of patients on statins before development of pneumonia or other infection were less likely to develop sepsis, die from sepsis, or have complications leading to intensive care unit admission. No study has examined the addition of statins as an adjunctive therapy once pneumonia has developed.

Oral hypoglycaemic agents, such as glitazones, may have anti-inflammatory effects similar to corticosteroids in patients with community-acquired pneumonia, and glyburide has been associated with significantly lower mortality in patients with severe melioidosis than in patients without diabetes or patients taking other diabetes agents. These findings warrant clinical investigation to establish whether oral hypoglycaemic agents are potential host-directed therapies for severe community-acquired pneumonia.

*Helicobacter pylori* has emerged as a major human pathogen because of its role in gastric cancer (classified as a type 1 carcinogen) and gastric ulcers. More than 50% of the world’s population is infected with the pathogen, which has co-evolved with human beings for almost 60 000 years. Raised concentrations of interleukin 1β and TNFα in the gut of individuals with *H pylori* infection have been postulated as risk factors for inflammatory tissue transformation and damage, and carcinogenesis. Efforts to develop host-directed therapies against *H pylori* infection have focused on neutralisation of these pro-inflammatory cytokines with monoclonal antibodies (eg, anti-interleukin 1β, gevokizumab, anti-TNFα, and adalimumab) during the course of antibiotic treatment to clear the infection. Vitamin D3 also has potential for use as a host-directed therapy for *H pylori* infection. In a preclinical study with a gastric epithelial cell line (GES-1) infected with *H pylori*, vitamin D3 supplement augmented killing of intracellular bacteria via induction of cathelicidin and β-defensin 4.

*Bordetella pertussis* remains an important cause of morbidity and mortality. Antibiotics do not substantially affect the course of whooping cough disease unless treatment is started early after symptom onset. Many patients develop long-term pulmonary damage. Immuno-therapy with antipertussis toxin antibodies might confer protection against more severe forms of whooping cough. Halperin and colleagues investigated the use of multiple doses of intravenous antipertussis immunoglobulin in 25 infants with pertussis infection and noted an increase in serum antipertussis antibody titres, a decline in lymphocytosis, and a reduction in paroxysmal coughing compared with baseline; however, findings from more recent studies of antipertussis immunoglobulin were not promising. Manipulation of the sphingosine-1-phosphate signalling pathway, involved in several immunological processes including lymphocyte trafficking, might have therapeutic benefits in reversing the pathological outcome in pertussis disease (appendix).

The number of infections with antibiotic-resistant *Neisseria gonorrhoeae* is increasing worldwide. The histone deacetylase inhibitor sulforaphane, which induces expression of antimicrobial peptides (eg, secretory leukocyte protease inhibitor and β-defensin 2), has been shown to augment the activity of antibiotics against multidrug-resistant *N gonorrhoeae*, thus showing potential as a host-directed therapy. Supernatants from human endocervical carcinoma cells pre-treated with sulforaphane potentiated better bacterial killing in combination with sublethal doses of ciprofloxacin and cefixime compared with antibiotics alone. Furthermore, sulforaphane treatment in *N gonorrhoeae*-infected female mice resulted in better control of bacterial load and reduced inflammation. Treatment of cervical cells with sulforaphane in combination with antibiotic therapy might reduce the amount of antibiotic needed to eradicate *N gonorrhoeae*. See appendix for discussion of host-directed therapies for bacterial sepsis.

**Viral infections**

HIV targets and infects human CCR5-positive T cells and causes AIDS, impeding CD4 T-cell-mediated responses to a wide range of microbes. In 2014,
### Bacterial infections

| Example of host-directed therapy | Mechanism of action | Developmental stage |
|----------------------------------|---------------------|---------------------|
| **Mycobacterium tuberculosis** |                     |                     |
| Repurposed drug*                 | Imatinib, verapamil, metformin, ibuprofen | Modulation of inflammation and activation of intracellular antimicrobial defences | Preclinical/clinical (early phase) |
| Cytokine therapy*                | Interleukin 2, GM-CSF, interferon γ, interleukin 12 (early stage) | Induction of pro-inflammatory cell signalling | Clinical (late phase) |
| Monoclonal antibody*             | Anti-TNFα, anti-interleukin 6, anti-VEGF | Reduction of tissue-destructive inflammation by cytokine neutralisation | Preclinical/clinical (early phase) |
| Monoclonal antibody*             | Anti-PO-1, anti-LAG3, anti-CTLA-4 | Activation and mobilisation of antigen-specific T cells by immune checkpoint inhibition | Preclinical |
| Vitamin*                         | Vitamin D3 | Activation and augmentation of intracellular antimicrobial defences (via interferon γ and interleukin-15 signalling) | Clinical (late phase) |
| Cellular therapy*                | Autologous mesenchymal stromal cells, T cells | Neutralisation of tissue-destructive inflammation, enhancement of organ repair, and potentiation of antigen-specific immune responses | Clinical (late phase) |

| Streptococcus pneumoniae         |                     |                     |
| Repurposed drug*                | Prednisone | Reduction of tissue-destructive inflammation by activating the glucocorticoid pathway | Clinical (late phase; also in current practice) |
| Repurposed drug*                | Ibuprofen, statins, indomethacin, aspirin | Reduction of tissue-destructive inflammation by inhibiting prostaglandin release via cyclooxygenase inhibition, regulation of MHC molecules | Clinical (late phase) |
| Repurposed drug*                | Gilbenclamide | An oral hypoglycaemic agent that modulates voltage-gated calcium channels, leading to immunomodulatory effects | Clinical (early phase) |
| Antibiotic*                     | Azithromycin, erythromycin | Reduces local tissue inflammation through anti-inflammatory activities | Clinical (current practice) |

| *Helicobacter pylori*           |                     |                     |
| Monoclonal antibody*            | Anti-interleukin 1β, anti-TNFα (late stage) | Reduction of tissue-destructive inflammation by cytokine neutralisation | Preclinical |
| Vitamin*                        | Vitamin D3 | Activation and augmentation of intracellular antimicrobial defences (via interferon γ and interleukin-15 signalling) | Preclinical |

| *Bordetella pertussis*          |                     |                     |
| Repurposed drug*                | Fingolimod | Activates the sphingosine-1-phosphate pathway to improve antigen-specific lymphocyte responses, as well as reduced hyper-inflammation | Preclinical |
| Monoclonal antibody*            | Antipertussis toxin antibodies | Reduces toxin load via infusion of intravenous immunoglobulins | Clinical (in current practice) |

| *Neisseria gonorrhoeae*         |                     |                     |
| Repurposed drug*                | Sulforaphane | Increased histone acetylation to enhance gene transcription | Preclinical |
| Recombinant protein*            | Secretory leucocyte protease inhibitor, β-defensin 2 | Host-derived antimicrobial peptides with bactericidal effects | Preclinical |

### Viral infections

| HIV                               |                     |                     |
| Repurposed drug*                  | Valproic acid, vorinostat | Reactivation of latent HIV infection and making new viral progeny susceptible to ART and immune attack by enhancing gene transcription | Clinical (early phase) |
| Monoclonal antibody*              | Anti-PO-1 | Activation and mobilisation of antigen-specific T cells via immune checkpoint blockade | Preclinical |
| Cellular therapy*                 | MSCs | Reduction of destructive inflammation and enhancement of tissue regeneration and organ repair | Not yet tested in HIV infection |

| Epstein-Barr virus                |                     |                     |
| Cellular therapy*                 | CD19 CAR (for Epstein-Barr virus [EBV]-B-cell lymphoma), in-vitro-expanded EBV-specific CD8 CTLs | Depletion of viral reservoirs to deter progression to lymphoma | Clinical (mid phase) |

| Cytomegalovirus                   |                     |                     |
| Monoclonal antibody*              | Viral envelope protein-targeted IgG | Neutralises virus and reduces viral load | In clinical use |
| Cellular therapy*                 | In-vitro-expanded cytomegalovirus-specific CD8 CTLs | Depletion of viral reservoirs to avoid fulminant viraemia in immunocompromised individuals | In clinical use |

| Adenovirus                        |                     |                     |
| Cellular therapy*                 | In-vitro-expanded adenovirus-specific CD8 CTLs | Depletion of viral reservoirs to avoid fulminant viraemia in immunocompromised individuals | In clinical use |

| Hepatitis C virus                 |                     |                     |
| Repurposed drug*                  | Mitavirsen (SPC3649) | Antisense RNA targeting miR-122 for modulation of fatty acid metabolism to reduce viral burden in host cells | Clinical (early phase) |
| Monoclonal antibody*              | Anti-PO-1 | Activation and mobilisation of antigen-specific T cells via immune checkpoint blockade | Clinical (early phase) |
| Cytokine therapy*                 | Pegylated interferon α and β | Potentiation of pro-inflammatory antiviral immune response | Clinical (early phase) |

*(Table 1 continues on next page)*
co-infection with HIV accounted for 12% of the 1.5 million deaths from tuberculosis worldwide. Although HIV-reactive CD8 cytotoxic T lymphocytes and antibodies are present in individuals with HIV infection, the protective role of CD8 T cells and humoral immune responses are rather limited when CD4 T-cell numbers are low. Moreover, expression of programmed cell death protein 1 (PD-1) by circulating HIV-specific CD8 cytotoxic T lymphocytes isolated from patients with AIDS compromises their responsiveness to antigenic stimuli because of cellular exhaustion. Antiretroviral therapy (ART) promotes immune reconstitution (increase in CD4 T-cell numbers) in individuals undergoing treatment, in addition to reducing viral load and restoring a diverse T-cell receptor repertoire. This immune reconstitution, however, does not purge latent viral reservoirs in the host, nor sustain HIV-specific CD8 cytotoxic T-lymphocyte repertoires. Immune reconstitution inflammatory syndrome is an important clinical manifestation in patients with HIV–tuberculosis co-infection early after initiation of ART. Overt Th1-mediated immune responses result in pro-inflammatory cytokine storms (of

(Table 1 continues on next page)
which interleukin 6 is an important component) and hyperactivation of immune cells, mediating extensive tissue damage. At present, repurposing of histone deacetylase inhibitors—eg, vorinostat, panobinostat, and valproic acid—has shown promise as host-directed therapy for improved clinical management of HIV/AIDS. These clinically approved drugs are able to reactivate latent virus reservoirs in the host and expose new virus progeny to ART as well as immune attack. The encouraging results of early-phase clinical trials of histone deacetylase inhibitor treatment of latent HIV infection could revolutionise ART. Since PD-1 expression on HIV-specific CD8 cytotoxic T lymphocytes is a barrier to effective antiviral immune responses in patients with AIDS, timely blockade of the PD-1/programmed death-ligand 1 (PD-L1) pathway could be a viable option to pursue. In-vitro blockade of PD-L1 has already been shown to improve anti-HIV CD8 cytotoxic T-lymphocyte responses, marked by increased proliferation and production of cytokines and cytotoxic molecules. Faster recovery of immune competence in lymphopenic hosts has been seen in HIV-positive patients after treatment with recombinant interleukin 7.

Epstein-Barr virus (EBV) is a human herpesvirus, which is ubiquitous and remains largely latent in nature; at least 95% of the world’s population is infected with the virus. EBV has tropism for B cells. It causes a wide range of clinical syndromes, from self-limited infectious mononucleosis to lymphoproliferative syndromes and B-cell lymphomas. Chimeric antigen receptors designed against the B-cell surface antigen CD19 are currently approved for eliminating latent viral reservoirs in the patient to decrease chances of developing B-cell lymphomas. This approach is also feasible for patients with EBV-associated B-cell lymphoma. Alternatively, transfer of EBV-specific CD8 cytotoxic T lymphocytes initially isolated from patients, and cultured and expanded ex vivo, has been clinically tested with much success. Not only CD8, but also CD4 T-cell responses have been shown to mediate control of EBV-infected cells. Interleukin 21, produced by CD4 T cells, has been shown to be involved in the EBV nuclear antigen 2 (EBNA-2)-independent expression of latent membrane protein 1 (LMP-1) in EBV-carrying type 2 cells.

Cytomegalovirus is another ubiquitous human herpesvirus that infects the lungs, eyes, CNS, and gastrointestinal tract, but can cause serious disease in adults and children. In particular, patients who have recently undergone haemopoietic stem-cell transplantation (HSCT) are at increased risk of developing clinical cytomegalovirus disease associated with the cytomegalovirus status of the donor and the recipient of HSCT. Immune control is largely attributed to antigen-specific CD8 cytotoxic T lymphocytes, although cell activation is noticeably subdued after HSCT as a result of immunosuppressive therapy. For host-directed therapies, transfer of autologous or allogeneic antigen-specific CD8 cytotoxic T lymphocytes has been investigated, mainly in HSCT settings. The timing of this strategy is crucial to avoid cytomegalovirus-associated immune reconstitution inflammatory syndrome.

Hepatitis C virus (HCV) causes at least 3% of liver diseases worldwide, and is the leading cause of liver cirrhosis and hepatocellular carcinoma. Acute and chronic stages of HCV infection of the liver promote T-cell exhaustion, which, as in HIV infection, is characterised by PD-1 expression on virus-specific CD4 and CD8 cytotoxic T lymphocytes. Another immune checkpoint, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), is also expressed on exhausted T cells and reduces the immune reactivity of anti-HCV effector T cells to virus-infected...
| Class or type | Mechanism of action | Host effect | Developmental stage for tuberculosis |
|--------------|---------------------|-------------|--------------------------------------|
| **Mitochondrial respiration and fatty acid oxidation** | | | |
| Metformin111,94 | Biguanide | Interrupts the mitochondrial respiratory chain and induces ROS production, increases mitochondrial biogenesis and respiration | Enhanced killing of intracellular Mycobacterium tuberculosis via ROS production; improved control of bacterial burden and reduced lung pathology in mice; enhanced T-cell responses; might improve maintenance of memory CD8 T cells via increased FAO; promotes generation of CD8 T-cell memory against tumour engraftment in experimental TRAF6-deficient mice by restoring FAO, possibly via AMPK activation; increases mitochondrial biogenesis and hence respiration in rabbit renal proximal tubular cells | Preclinical |
| Niraparib95 | PARP inhibitor | Inhibition of PARP-1 and PARP-2 activity, and impairs repair of DNA single strand breaks | Restores mitochondrial respiratory function in human myotubes, also by improved FAO; might promote maintenance of antituberculosis memory CD8 T cells | Preclinical |
| Interleukin 1559,97 | Cytokine | Involved in maintenance and possibly proliferation of CD8 T cells | Increases mitochondrial mass and FAO in memory CD8 T cells to prolong survival in experimental mice | Preclinical |
| **Arachidonic acid metabolism** | | | |
| Aspirin98 | NSAID | Increased lipoxin A4 production to reduce TNFα levels and achieve eicosanoid balance during chronic inflammation | Dampening of TNFα-induced hyperinflammation to aid tissue repair and control burden of M tuberculosis | Preclinical |
| Zileuton99 | Leukotriene synthesis inhibitor | Blocks leukotriene production by disrupting lipoxigenase activity; promotes prostaglandin production via cyclooxygenase activation | Increases PGE2 levels and augments interleukin-1β-mediated immune control of tuberculosis in mice; promotes reduced lung M tuberculosis burden and pathology | Preclinical |
| Ibuprofen100,101 | NSAID | Blocks production of prostaglandins possibly by inhibiting cyclooxygenase activity | Reduces lung pathology and mycobacterial burden in a highly susceptible mouse model of tuberculosis | Clinical (early phase) |
| **Corticosteroid metabolism** | | | |
| Prednisone102 | Glucocorticoid receptor antagonist | Forms a complex with glucocorticoid receptor and triggers transcription of several important host genes (ie, iNOS, cyclooxygenase-2, collagenase) | Use in patients with community-acquired pneumonia showed improved survival; results in patients with tuberculosis require further validation | Clinical (mid-late phase) |
| **Histone acetylation** | | | |
| Valproic acid and vorinostat104,105 | Histone deacetylase inhibitor | Acetylation of lysine residues on histones to promote DNA unwinding and gene transcription | Valproic acid and vorinostat can activate latent HIV reservoirs and increase ART efficacy as well as CD8 T-cell activity; both drugs can improve efficacy of isoniazid and rifampicin against intracellular M tuberculosis | Preclinical |
| Phenylbutyrate104,105 | Histone deacetylase inhibitor | Acetylation of lysine residues on histones to promote DNA unwinding and gene transcription | Augments vitamin D3 activity, cathelicidin production, and MAPK signalling to kill intracellular M tuberculosis | Clinical (early phase) |
| **Host cell cytotoxicity** | | | |
| Cyclophosphamide106,107 | Alkylling agent | CYP450 metabolism of cyclophosphamide produces chemical species that can alkylate DNA guanine to reduce cell proliferation. Cells highly expressing ALDH are resistant to cyclophosphamide | Abrogation of regulatory T-cell responses, and potentiation of RCC vaccine candidate efficacy in clinical trials, with induction of CD8 T-cell responses; might increase efficacy of the BCG vaccine | Not yet tested in tuberculosis |
| Etoposide108,109 | Topoisomerase inhibitor | Blockade of DNA topoisomerase II to prevent re-ligation of nascent DNA strands | Depletion of pathogenic inflammatory T cells in influenza-induced ILH | Preclinical |
| **Modulation of ion efflux channels** | | | |
| Verapamil110 | Calcium-channel blocker | Modulation of voltage-gated calcium-channel activity for maintenance of cellular ionic homeostasis | Improves efficacy of conventional and novel antituberculosis drugs in M tuberculosis-infected mice | Preclinical |
| Carbamazepine111 | Sodium-channel blocker | Anticonvulsant; acts via voltage-gated sodium-channel downmodulation and activation of GABA receptors for reduced sensitivity to neuropathic pain. Activates AMPK to induce autophagy | Shown to induce inositol depletion-dependent autophagic killing of intracellular M tuberculosis in macrophages; augments reduced lung pathology and improved immune responses in the mouse model of tuberculosis | Preclinical |
| Statins112,113 | Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme reductase | Block biosynthesis of endogenous cholesterol | Simvastatin can reduce M tuberculosis CFUs (human macrophages and mice) | Preclinical |
| **Inhibition of tyrosine kinases** | | | |
| Imatinib mesylate114 | Inhibitor of BCR-ABL tyrosine kinase | Induces apoptotic death of cancerous B cells, and cells expressing related kinases | Reduces CFU load and pathology in lungs of M tuberculosis-infected mice; induces myelopoiesis | Preclinical (about to enter early phase clinical trials) |

(Table 2 continues on next page)
### Table 2: Developmental pipeline of host-directed therapies for adjunct treatment of drug-sensitive and drug-resistant tuberculosis, by host pathway

| Class or type | Mechanism of action | Host effect | Developmental stage for tuberculosis |
|---------------|---------------------|-------------|--------------------------------------|
| Vitamin D3<sup>115,116</sup> | Vitamin induces cathelicidin production, improves antigen processing and presentation, augments response to interferon-γ signalling | Kills intracellular M tuberculosis and improves T-cell responses | Clinical (late phase) |
| GM-CSF, interleukin 2, and interferon γ<sup>117</sup> | Cytokine induces cathelicidin production, improves antigen processing and presentation, augments response to interferon-γ signalling | Variable results but with a generally positive outcome following treatment, coupled with reduction in sputum AFB | Clinical (mid-late phase) |
| Ipilimumab (anti-CTLA-4)<sup>118,119</sup> | Monoclonal antibody blockade of CTLA-4 to undo T-cell exhaustion, restores interleukin-2 secretion and signalling | CTLA-4 inhibition in melanoma increases CD8 T-cell activity and tumour regression; might improve CD8 T-cell activity against M tuberculosis-infected cells | Preclinical |
| Nivolumab or pembrolizumab (anti-PD-1)<sup>120–122</sup> | Monoclonal antibody blockade of PD-1 to restore lymphocyte functionality. Also, PD-L1 blockade on the surface of APCs contributes to T-cell activation | PD-1 blockade potentiates in-vitro killing of M tuberculosis-infected macrophages by CD4 T cells in an interferon-γ-dependent manner and prevents apoptosis of T cells; downregulation of PD-1 on CD4 T cells is commensurate with antituberculosis treatment | Preclinical |
| Anti-LAG3<sup>123</sup> | Monoclonal antibody blockade of LAG3 to abrogate regulatory T-cell interaction with activated effector CD4 and CD8 T cells | Blockade of LAG3 can potentiate targeted CD8 CTL responses in patients with solid tumours. In tuberculosis, low LAG3 expression may be reflective of successful containment of tuberculosis infection | Preclinical |
| Adalimumab (anti-TNFα)<sup>124</sup> | Monoclonal antibody removal of excess TNFα from tissue and circulation | Successfully used salvage therapy in a patient with severe pulmonary tuberculosis | Clinical (compassionate use) |
| Siltuximab (anti-interleukin 6)<sup>125,126</sup> | Monoclonal antibody removal of excess interleukin 6 from tissue and circulation | Effective against arthritis and Castleman’s disease; used prospectively in patients with HIV/tuberculosis co-infection may reduce mortality from tuberculosis-associated IRIS | Preclinical |
| Bevacizumab (anti-VEGF)<sup>127</sup> | Monoclonal antibody blockade of VEGF-induced neovascularisation in tissue | Disrupts neovascularisation within lung granulomas in a rabbit model of tuberculosis; improves small-molecule penetration into granulomas and increases air supply, might therefore improve antituberculosis drug efficacy | Preclinical |
| BM-MSCs<sup>128</sup> | Cell-based therapy BM-MSCs can reduce destructive inflammation, regenerate tissue, and restore positive modulation of immune responses, secretion of soluble factors, and activation of regulatory T cells | Autologous MSC reinfusion in a phase 1 trial in Beloans of patients with multidrug-resistant tuberculosis was safe and reconstituted anti-M tuberculosis T-cell responses; a phase 1 study is underway in Durban, South Africa | Clinical (early phase) |

ROS = reactive oxygen species. FAO = fatty acid oxidation. TRAF6 = tumour necrosis factor receptor-associated factor 6. AMPK = 5'-adenosine monophosphate-activated protein kinase. PARP = poly (ADP-ribose) polymerase. NSAID = non-steroidal anti-inflammatory drug. TNFα = tumour necrosis factor α. PGE2 = prostaglandin E2. iNOS = inducible nitric oxide synthase. ART = antiretroviral therapy. MAPK = mitogen-activated protein kinase. CYP450 = cytochrome P450. ALDH = aldehyde dehydrogenase. RCC = renal cell carcinoma. HLH = haemophagocytic lymphohistiocytosis. GABA = γ-aminobutyric acid. CFUs = colony forming units. PARP = poly (ADP-ribose) polymerase. NSAID = non-steroidal anti-inflammatory drug. TNFα = tumour necrosis factor α. PGE2 = prostaglandin E2. iNOS = inducible nitric oxide synthase. ART = antiretroviral therapy. MAPK = mitogen-activated protein kinase. CYP450 = cytochrome P450. ALDH = aldehyde dehydrogenase. RCC = renal cell carcinoma. HLH = haemophagocytic lymphohistiocytosis. GABA = γ-aminobutyric acid. CFUs = colony forming units.

### Notes
- The current first-line treatment for HCV infection is a combination regimen of direct-acting antiviral drugs, which mandatorily includes the nucleotide analogue sofosbuvir. Despite their high efficacy, the high financial cost of direct-acting antiviral drugs is a barrier to provision of HCV treatment.
- The anti-PD-1 monoclonal antibody nivolumab has been shown to induce productive clinical responses in patients with HCV infection, marked by pronounced viral load reduction. No adverse side-effects were noted, although some important observations were reported. In one patient receiving nivolumab only, a transient, grade 4 rise in alanine transaminase concentration was concomitant with maximum HCV viral load reduction (4·55 log IU/mL) 22 days after treatment. Another patient, who also had diabetes
mellitus and was receiving metformin treatment, had an increase in blood glucose concentrations, requiring insulin therapy. Anti-PD-1 therapy has been used for treatment of melanoma and other solid cancers, including HCV-induced hepatocellular carcinoma in combination with anti-CTLA-4 (NCT01658878). HCV-infected hepatocytes secrete newly formed viruses bound to apolipoprotein B (apoB), thus making increased apoB expression a risk factor for infection and progression to active hepatitis, and a potential target for host-directed therapy. MicroRNA-122 (miR-122) is highly expressed in the liver and has an important role in fatty-acid metabolism. Notably, increased levels of circulating miR-122 in serum samples from patients with HCV infection (genotypes 1 and 3) qualifies it as a disease biomarker and target for host-directed therapy. A phase 2 clinical trial of miravirsen (SPC3649; Santaris Pharma, Hørsholm Municipality, Denmark), an antisense oligonucleotide targeting miR-122, in patients with chronic HCV infection, has recently been completed (NCT01200420), and previous preclinical assessments showed promising antiviral effects. A phase 2 clinical trial of miravirsen (SPC3649; Santaris Pharma, Hørsholm Municipality, Denmark), an antisense oligonucleotide targeting miR-122, in patients with chronic HCV infection, has recently been completed (NCT01200420), and previous preclinical assessments showed promising antiviral effects.

Influenza virus has caused several pandemics with millions of deaths worldwide. Many patients with influenza succumb to extensive lung pathology or secondary bacterial pneumonia, and resistance to current neuraminidase inhibitors presents a major hurdle to management of future pandemics. Immunosuppressive treatment with etoposide to dampen the cytokine storm-induced lung pathology was clinically beneficial in patients with severe influenza infection. DAS181 (fludase; Ansun Biopharma, San Diego, CA, USA) is a sialidase fusion peptide that cleaves off the sialic acid residues on host epithelial cell-surface receptors. Following approval by the US Food and Drug Administration (FDA), DAS181 has been used in two HSCT recipients with parainfluenza infection; the first patient died whereas the second recovered. Clinical benefit and reduction of viral load has been reported from a phase 2 clinical trial of DAS181 in patients with pneumonia caused by either influenza B or the 2009 H1N1 pandemic strain. Several immunomodulatory drugs, statins, angiotensin-II-receptor blockers, angiotensin-converting enzyme inhibitors, peroxisome proliferator-activated receptor-γ (PPARγ) and PPARα agonists (glitazones and fibrates, respectively), and adenosine monophosphate-activated kinase agonists (eg, metformin) have been suggested to modify the host response to severe influenza to improve survival, since these interventions have been shown to reduce mortality in mice infected with influenza virus. In an observational study of more than 3000 patients admitted to hospital with laboratory-confirmed influenza, statins reduced the number of deaths in hospital and within 30 days of discharge by 41%. An observational study showed that inpatient treatment with angiotensin-II-receptor blockers, angiotensin-converting enzyme inhibitors, and statins reduced 30-day pneumonia mortality by 53%, 42%, and 32%, respectively.

In the 2014–15 epidemic of Ebola virus disease, this disease caused more than 28639 cases and 11316 deaths in three west African countries. Clinical trials of experimental antiviral agents, antibody preparations, and vaccines were completed. The clinical success of treating patients with Ebola virus infection with convalescent plasma from individuals who survived the 1976 and 1995 disease outbreaks in the Democratic Republic of the Congo prompted use of this strategy in the 2014 Ebola outbreak in west Africa. Although this intervention provided some survival benefit, acute kidney or lung injury were reported; however, these adverse effects could not be directly attributed to convalescent plasma transfusion.

New treatment strategies targeting host factors in Ebola virus disease are in development. Recombinant nematode anticoagulant protein c2 (rNAPc2), an anticoagulant with FDA approval for treatment of thrombosis, has shown promising preclinical data in Ebola virus-infected monkeys, although no clinical trials are currently listed. Endothelial dysfunction causes the fluid and electrolyte imbalances seen in patients with Ebola virus infection; in-vitro studies have shown that statins and angiotensin-II-receptor blockers preserve or restore endothelial barrier integrity. These drugs could be considered for treating the host response in these patients. In Sierra Leone, about 100 patients with Ebola virus infection were treated with this combination, and reports suggest substantial extension of survival.

Dengue virus belongs to the genus of flaviviruses, which also includes yellow fever virus, West Nile virus, tick-borne encephalitis virus, and Zika virus; all are arthropod-transmitted infections. Four different serotypes of dengue virus exist, and infection with one serotype does not protect against the other. Dengue virus infection can lead to establishment of severe haemorrhagic disease, and in some cases leads to shock syndrome, which is fatal. As a host-directed therapy, lovastatin, a known modulator of cholesterol metabolism, was shown to inhibit replication of dengue virus in A549 human epithelial cells. Other repurposed drugs have also been clinically tested: ivmectin, dasatinib, and ciclosporin. Additionally, use of type 1 interferon (α or β) and interferon γ has shown promising results in animal models (non-human primates). rNAPc2 could also be useful in managing vasculopathy during dengue haemorrhagic fever or shock syndrome, but this approach requires clinical investigation.

Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated in June, 2012, in Jeddah, Saudi Arabia, from a patient who died of severe respiratory infection and multiorgan failure. MERS-CoV is associated with high mortality in patients with comorbidities and there are no effective anti-MERS-CoV antiviral agents or therapeutics. The lung pathology seen...
in patients with MERS probably represents the end result of a fine balance of host immune and MERS-CoV interactions. In-vitro laboratory investigation identified the membrane-bound form of dipeptidyl peptidase 4 to be the cardinal host-cell receptor for virus entry. Pneumonia is a common feature in patients with MERS and the high mortality caused by MERS-CoV is attributable to acute lung injury or development of acute respiratory distress syndrome (ARDS). ARDS is associated with leaky alveolar–capillary interfaces with pulmonary oedema, hypoxia, polymorphonuclear leucocytes or lymphocytic cellular infiltrates, and an aberrant immune response, with upregulation of pro-inflammatory cytokines, including interferon γ, which results in further tissue damage and deterioration of lung function. Analysis of serum and bronchoalveolar lavage fluid samples from patients who died from MERS-CoV infection showed non-productive inflammatory immune responses and induction of interleukin 6 and interleukin 17A. Patients with acute lung injury or ARDS died from the disease. Blockade of the pro-inflammatory cytokines interleukin 17A and interleukin 6 during severe disease might be useful as adjunct therapy and needs to be assessed in clinical trials. Additionally, reinfusion of bone marrow mesenchymal stem cells might also help ameliorate lung pathology in critically ill patients. Potential host-directed therapies to improve treatment outcomes of MERS are shown in table 1.

Parasitic diseases

*Plasmodium falciparum* malaria kills up to 1 million people worldwide every year. Individuals with *P falciparum* infection often develop severe clinical symptoms such as brain damage and multiple organ failure. Up to 25% of cases of severe clinical malaria are fatal even with access to the best health care, partly because the parasite triggers inflammation that damages vital organs. Case fatality rates for severe malaria remain high even in the best clinical settings because antimalarial drugs act against the parasite without alleviating life-threatening inflammation. Drug resistance now threatens efficacy of artemisinin-based therapies. Ferrochelatase, an enzyme important for haem biosynthesis in human erythrocytes, has been reported to be instrumental in parasite survival. Human erythrocytes deficient for ferrochelatase (from patients with erythropoietic protoporphyria) are more resistant to *P falciparum* growth, and pharmacological inhibition of host ferrochelatase in vitro abrogated parasite replication in healthy human erythrocytes. Desferrioxamine is a potent inhibitor of ferrochelatase, and could be considered for repurposing in human malaria.

Excess TNFα production is involved in the pathogenesis of severe malaria. In a clinical study that included 20 Gambian children in malaria-associated coma, treatment with an anti-TNFα antibody reduced parasite load in a dose-dependent manner and had noteworthy antipyrogenic effects. The use of anti-TNFα drugs (eg, adalimumab, etanercept) in severe malaria need to be further investigated in clinical trials.

A small synthetic peptide known as innate defence regulator (IDR)-1018 seems to have broad therapeutic potential, including in-vivo activity in murine models by enhancement of wound healing and protection against *Staphylococcus aureus*, multidrug-resistant *M tuberculosis*, herpes simplex virus, and inflammatory disorders, including cerebral malaria. Recent studies of the *Plasmodium berghei* ANKA model of experimental cerebral malaria showed that IDR peptides prevented CNS inflammation and protected mice from experimental cerebral malaria, improving survival. IDR peptides enhance the beneficial aspects of the initial immune response, while dampening harmful tissue damage by downregulating the secretion of pro-inflammatory cytokines including TNFα and interleukin 1β. Co-administration of IDR-1018 with standard first-line antimalarial drugs (pyrimethamine and chloroquine) increased survival in infected mice. Thus, IDR peptides could serve as adjunctive host-directed therapy for severe disease in combination with antimalarial treatment. Leishmania spp cause a range of clinical disease including cutaneous, mucocutaneous, and visceral involvement. Like most intracellular pathogens, *Leishmania* spp parasites are difficult to kill because their localisation protects against immune responses and chemotherapy. Drug treatments have limited efficacy, have to be used for lengthy periods of time, and the systemic side-effects sometimes outweigh any clinical benefits. Thus, successful treatment of diseases caused by intracellular pathogens might need combination therapies and effective delivery systems. Imiquimod and resiquimod are currently used for treatment of leishmaniasis; both trigger Toll-like receptor (TLR)-7-mediated innate immune responses, inducing production of interleukin 6, type 1 interferons, and TNFα, and thus act in a host-directed manner. Overproduction of TNFα in *Leishmania braziliensis* infection contributes to mucosal tissue damage, consequently leading to development of mucocutaneous leishmaniasis. In this case, a combination of antileishmanial drugs and anti-TNFα (adalimumab) during active *L braziliensis* infection might yield a clinical response. In preclinical studies, delivery of nanocapsulated doxorubicin (in a formulation that included chondroitin sulfate) to hamsters increased killing of leishmanial promastigotes via augmentation of Th1-mediated immune responses via induction of interferon γ, TNFα, and interleukin 2 release in addition to direct antiparasitic activity. Sequential chemoimmunotherapy, with a single low dose of liposomal amphotericin B and a novel T-cell-epitope-enriched DNA vaccine candidate (LEISHDNAVAX; Mologen AG, Germany) was tested as host-directed therapy. The vaccine candidate boosted the efficacy of a single suboptimal dose of liposomal amphotericin B in C57BL/6 mice. Polyhexanide is a cationic polymer, which is able to directly...
kill Leishmania major and to enhance host-directed killing by improving the delivery of immunomodulatory nucleic acids. Polyhexanide spontaneously binds CpG ODN (short synthetic oligodeoxynucleotides comprising cytosine triphosphate [C] and guanine triphosphate [G] residues in sequential order), forming stable nanopolymers that enhanced uptake of CpG ODN, potentiated antimicrobial killing, and reduced host-cell toxicity of polyhexanide.\(^{20}\) These findings warrant further investigation.

Trypanosoma spp cause human trypanosomiasis, two important vector-borne diseases: human African trypanosomiasis (also known as sleeping sickness; caused by Trypanosoma brucei gambiense and T brucei rhodesiense) and Chagas disease (caused by Trypanosoma cruzi).\(^{171}\) Severe pathology in patients with human African trypanosomiasis can lead to fatal meningoencephalopathy and in many cases coma.\(^{172}\) In Chagas disease, patients are prone to infectious myocarditis or meningoencephalitis, or both, which are often life-threatening, and progressive damage of the autonomic nervous system occurs with organ enlargement and failure.\(^{173}\)

In mouse models of T brucei infections, equilibrium between early onset of Th1 responses (interferon γ, TNFα) and late Th2 responses (interleukin 4, interleukin 10) can control parasitaemia and associated pathology.\(^{45}\) Additionally, interferon-γ-driven nitric oxide, MHC-I antigen processing and presentation, and CD8 cytotoxic T-lymphocyte activation have a role in eliminating parasite reservoirs in macrophages.\(^{46}\) In human beings, cytokine analysis of cerebrospinal fluid specimens showed that patients with late-stage human African trypanosomiasis have raised levels of pro-inflammatory cytokines, including TNFα, interleukin 6, interleukin 8, monocyte chemotactic protein 1 (MCP-1; also known as CCL2), and macrophage inflammatory protein (MIP)-1α, among others.\(^{85}\) This destructive inflammation might be amenable to cellular therapy in late-stage human African trypanosomiasis, whereas immunostimulatory treatment with vitamin D3, interferon γ, and interleukin 2 could be useful at early stages. Interferon-γ-induced apolipoprotein 1 is a known host factor with antitrypanosomal activity. Thus, activating the immune system at an early stage with interferon γ could help control burden of parasitaemia via different effector mechanisms. Since the immune response profile in Chagas disease is similar to that in human African trypanosomiasis,\(^{77}\) host-directed therapies relevant to human African trypanosomiasis might also benefit patients with T cruzi infection, in addition to antiparasitic therapy.

Schistosomiasis affects more than 250 million people in 78 countries,\(^{23}\) and is caused by the trematode parasites of the genus Schistosoma. Major clinical manifestations arise from pathology due to granulomatous reaction around the ova in all major organs of the body, especially the urinary and gastrointestinal tracts.\(^{25}\) The antischistosomal immune response milieu mainly consists of Th1 cytokines (interferon γ, TNFα, interleukin 12p40) and interleukin 17. Interleukin 6 and interleukin 1β also seem to have an important role early after infection with Schistosoma spp cercariae.\(^{87}\) In interleukin-10-deficient mice repeatedly infected with Schistosoma mansoni, CD4 T-cell activity was more pronounced, targeted, and efficient, upon exposure to schistosoma antigen preparation.\(^{24}\) This finding, if extrapolated to human beings, would suggest that multiple exposures to S mansoni might reduce T-cell responsiveness in an interleukin-10-dependent manner and hence, weaken productive cellular immune responses. Use of interleukin 2 and interferon γ might help to recover T-cell responses in patients in endemic countries. Notably, the use of Th2 cytokines such as interleukin 25 and interleukin 33 in a mixture with schistosomal glyceraldehyde-3-phosphate dehydrogenase and peroxiredoxin in a post-exposure vaccination attempt resulted in immense reduction of migrating cercariae in S mansoni-infected mice.\(^{88}\)

Conclusions
Host-directed therapies targeting host immune and inflammatory pathways to enhance immune responses and alleviate immunopathology could benefit treatment outcomes in a range of bacterial, viral, and parasitic diseases. The variability in the potential of adjunct host-directed therapies to deliver clinically meaningful benefit for each pathogen demands definition. This definition will in part depend on how effective the standard antimicrobial therapy is, and whether tissue damage or other events represent therapeutic targets that otherwise are not addressed by conventional treatment. The focus on host-directed therapeutic strategies across various infectious diseases will require more investment for multidisciplinary research collaborations between academic and industrial partners to develop and take forward the assessment of host-directed therapies.
Review

Contributors
AZ, MM, and MR developed the first drafts of the manuscript, and the draft of the revisions. All authors contributed to the writing of subsequent and final drafts.

Declaration of interests
We declare no competing interests.

Acknowledgments
AZ receives support from the European Union FW7 RID-RTI Project, European Developing Countries Clinical Trials Partnership (TB-NEAT), and the National Institute for Health Research Biomedical Research Centre at University College of London Hospital, London, UK. CV receives support from the European Union FW7 RiD-RTI Project, and the National Institute for Health Research Biomedical Research Centre at University College of London Hospital, London, UK.

Contributors
1 GBD 2013 Mortality and Causes of Death Collaborators. Cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 1545–602.
2 Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 2012; 10: 243–54.
3 Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015; 385: 1511–18.
4 Rodriguez A, Mendia A, Sirvent JM, et al. and the Ibuprofen in Sepsis Study Group. The effects of ibuprofen on the physiology and pathophysiology of severe sepsis. J Infect Dis 2008; 198: 1352–57.
5 Hanly PJ, Roberts D, Dobson K, Light RB. Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. Lancet 1987; I: 351–54.
6 Ferrer M, Torres A, Baer R, Hernández C, Roca J, Rodríguez-Roisin R. Effect of acetylsalicylic acid on pulmonary gas exchange in patients with severe pneumonia: a pilot study. CHEST 1997; 111: 1094–100.
7 Bernard GR, Wheeler AP, Russell JA, et al. and the Ibuprofen in Sepsis Study Group. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336: 922–18.
8 Majumdar SR, McAlister FA, Eichle TD, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community-acquired pneumonia: population-based prospective cohort study. BMJ 2006; 333: 999.
9 Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31: 611–17.
10 Schlienger RG, Fedson DS, Sack SS, Sack H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007; 27: 325–32.
11 Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005; 6: 82.
12 Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. CHEST 2007; 131: 1006–12.
13 Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121: 1002–07.e1.
14 Thomsen RW, Riis A, Kormann JB, Christensen S, Johnsen SP, Sørensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 299900 patients. Arch Intern Med 2008; 168: 2081–87.
15 Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001; 33: 1352–57.
16 Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006; 34: 1080–86.
17 Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoeconomics Drug Saf 2009; 18: 269–75.
18 Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011; 342: d1462.
19 Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011; 39: 887–8.
20 Koh GC, Waaizukena TA, Breithach K, et al. Glyburide reduces bacterial dissemination in a mouse model of melioidosis. PLoS Negl Trop Dis 2013; 7: e2500.
21 Karlström A, Herston SM, Boyd KL, Tuomanen EI, McCullers JA. Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 2011; 204: 1358–66.
22 Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2003; 161: 1837–42.
23 Weiss K, Chong GH, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11: 592–91.
37 Scalon KM, Skerry C, Carbonetti NH. Novel therapies for the treatment of pertussis disease. Pathog Dis 2015; 73: htv074.
38 Bruss JW, Silver GR. Protective effects of pertussis immunoglobulin (P-IGIV) in the aerochallenge model. Clin Diagn Lab Immunol 1999; 6: 464–70.
39 Yedery R, Jerse A. Augmentation of cationic antimicrobial peptide production with histone deacetylase inhibitors as a novel epigenetic therapy for bacterial infections. Antibiotics 2015; 4: 44–61.
40 Leduc I, Jerse A. Host-directed therapeutics as adjunctive therapy for antibiotic-resistant Neisseria gonorrhoeae. Sex Transm Infect 2015; 91 (suppl 2): asir3 38.
41 Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Host-directed therapeutics as adjunctive therapy for testing or use in patients infected with Ebola. Feb 18, 2015. http://www.who.int/medicines/ebola-treatment/2015-0218_tables_of_ ebola_drugs_updated.pdf (accessed Feb 10, 2016).
42 Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor. Sci Rep 2013; 3: 3365.
43 Rothwell C, Lebreton A, Young Ng C, et al. Cholesterol biosynthesis inhibition allows latent viral expression. AIDS 2004; 18: 64–61. PubMed 15264790.
44 Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203: 2281–92.
45 Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase is a regulator of virus-specific T cell survival in HIV infection. J Exp Med 2011; 17: 466–72.
46 Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3: 129–42.
47 Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013; 99: 47–55.
48 Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of miR-122 expression of miRNA-122 in patients infected with HCV genotype 3. Pharmacotherapy 2010; 30: 554–61.
49 Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett 2014; 342: 1–8.
50 Brestrich G, Zwinger S, Roembild A, et al. Generation of 12CML-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy. J Immunother 2009; 32: 932–40.
51 Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 2004; 23: 383–88.
52 Oliveira KG, Malta FM, Nastrti AC, et al. Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3. Med Microbiol Immunol 2013; published online Aug 14. DOI:10.1007/s00281-013-0431-0.
53 Ottozon S, Parsley TB, Yang L, et al. In vitro antiviral activity and clinical and preclinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother 2015; 59: 599–608.
54 Reiner Z. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol 2015; 12: 565–75.
55 Gardiner D, Lalezari J, Lawitz E, et al. A randomized, double-blind, placebo-controlled assessment of BMS-93658, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013; 8: e68138.
56 Fedson DS. How will physicians respond to the next influenza pandemic? Clin Infect Dis 2014; 58: 213–37.
57 Oktoson S, Parsley TB, Yang L, et al. In vitro antiviral activity and clinical and preclinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother 2015; 59: 599–608.
58 Hovingh K, Jesselting J, Kastelein J. Efficacy and safety of mipomersen sodium (Kynamr). Expert Opin Drug Saf 2013; 12: 569–79.
59 Reiner Z. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol 2015; 12: 565–75.
60 Smith CM, Jerkovic A, Puy H, et al. Red cells from patients with chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010; 70: 147–65.
61 Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013; 99: 47–55.
62 Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013; 99: 47–55.
63 Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3: 129–42.
64 Vandermiet ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205: 13–19.
65 Fedson DS. How will physicians respond to the next influenza pandemic? Clin Infect Dis 2014; 58: 213–37.
66 Chalkias S, Mackenzie MR, Gay C, et al. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl Infect Dis 2014; 16: 141–44.
67 Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steighigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012; 206: 1844–51.
68 Fedson DS, Jacobson JR, Roddam OM, Opal SM. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. MBio 2015; 6: e00716-15.
69 Fedson DS, Roddam OM. Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 2015; 36: 80–84.
70 WHO. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola. Feb 18, 2015. http://www.who.int/medicines/ebola-treatment/2015-0218_tables_of_ebola_drugs_updated.pdf (accessed Feb 10, 2016).
71 Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMab. Sci Rep 2013; 3: 3365.
72 Geissert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362: 1953–58.
73 Rothwell C, Lebreton A, Young Ng C, et al. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 2009; 389: 8–19.
74 de Wispelaere M, LaCroix AJ, Yang PL. The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol 2013; 87: 7367–81.
75 Krishman MN, Garcia-Blanco MA. Targeting host factors to treat West Nile and dengue viral infections. Viruses 2014; 6: 683–708.
76 Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015; 28: 465–522.
77 Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32 (suppl 2): S223–31.
78 Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 2016; published online Feb 12. DOI:10.1038/nrd.2015.17.
79 Smith CM, Jerkovic A, Puy H, et al. Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites. Blood 2015; 125: 334–41.
80 Mansour SC, de la Fuente-Nunez C, Hancock RE. Peptide IDR-1018: modulation the innate system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J Pept Sci 2015; 21: 323–29.
81 Achtmann AH, Pilat S, Law CW, et al. Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. Sci Transl Med 2012; 4: 135ra64.
Review

82 Collier MA, Gallovic MD, Peine KJ, et al. Delivery of host cell-directed therapeutics for intracellular pathogen clearance. Expert Rev Anti Infect Ther 2013; 11: 1235–35.

83 Chaurasia M, Pawar VK, Jaiswal AK, Dube A, Palwal SK, Chaurasia MK. Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Tfh immune response. Int J Biol Macromol 2015; 79: 27–36.

84 Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010; 8: 419–33.

85 Bucheton B, MacLeod A, Jamonneau V. Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections. Parasite Immunol 2011; 33: 438–47.

86 Wang Y, Chen X, Gao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Int J Biol Macromol 2015; 79: 19–26.

87 El Ridi RA, Tallima HA. Novel therapeutic and prevention approaches for schistosomiasis: review. J Adv Res 2013; 4: 467–78.

88 El Ridi R, Tallima H. Vaccine-induced protection against murine schistosomiasis mansoni with larval excretory-secretory antigens and papan or type-2 cytokines. J Parasitol 2013; 99: 194–202.

89 WHO. Global tuberculosis report 2015. Geneva: World Health Organization, 2015. http://www.who.int/tb/publications/global_report/en/ (accessed Feb 10, 2016).

90 O’Carra A, Redford PS, McNab FW, Bloom GI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Ann Rev Immunol 2013; 31: 475–527.

91 Zumla A, Rao M, Parida SK, et al. Inflammation and tuberculosis: host-directed therapies. J Intern Med 2015; 277: 373–87.

92 Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009; 460: 103–07.

93 Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med 2014; 6: 253ra159.

94 Peule EA, Walsh Mc, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009; 460: 103–07.

95 Beeson CC, Beeson GC, Schnellmann RG. A high-throughput respiratory assay for mitochondrial biogenesis and toxicity. Cell Biochem 2010; 404: 73–81.

96 Pirinen E, Cantó C, Jo YS, et al. Pharmacological inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014; 19: 1034–41.

97 van der Windt GJ, Everts B, Chang CH, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 2012; 36: 68–78.

98 Montoya D, Inkeles MS, Liu PT, et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med 2016; 8: 350ra114.

99 Tobin DM, Roca FJ, Ray JP, Ko DC, Ramakrishnan L. An enzyme that inactivates the inflammatory mediator leukotriene B4 restricts mycobacterial infection. PLoS One 2013; 8: e67828.

100 Mayer-Barber KD, Andrade BB, Oland SD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type 1 interferon crosstalk. Nature 2014; 511: 99–103.

101 Bhatia J, Cartwright J, Verran D, et al. Humanized therapy results in significantly decreased tissue bacillary loads and increased survival in a murine neutropenic model of active tuberculosis. J Infect Dis 2013; 208: 199–202.

102 Iwanyi J, Zumla A. Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J Infect Dis 2013; 208: 185–88.

103 Critchley JA, Young P, Orton L, Garner P, Cotticoreiods for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13: 223–37.

104 Shan L, Deng K, Shoff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491–501.

105 Goussens AK, Wilkinson RJ, Martineau AR. Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-hydroxy-vitamin D3. PLoS Pathog 2013; 11: e1005007.

106 Kulkarni NN, V.Z., Huerknkes C, Agterberth B, Gudmundsson GH. Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: linkage to inflammatory and growth factor cytokines pathways. Mol Immunol 2015; 63: 330–39.

107 Hall AG, Tilley MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 1992; 6: 163–73.

108 Walter S, Weinschenk T, Stendzl A, et al. Multipeptide immune response to cancer vaccine JMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18: 1254–61.

109 Henter JI, Chow CB, Leung CW, Lau YL. Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet 2006; 367: 870–73.

110 Henter JI, Malmkvist-Kajjer K, Holsgaafse B, Bryesson YT, Palmér K. Cytotoxic therapy for severe swine flu A/H1N1. Lancet 2010; 376: 2176.

111 Gupta S, Tyagi S, Bishai WR. Voraparim increases the bacterial activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Antimicrob Agents Chemother 2015; 59: 673–76.

112 Schiebler M, Brown K, Hegri K, et al. Functional drug screening reveals antituberculosis as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through insulin deprivation. EMBO Mol Med 2015; 7: 127–39.

113 Parshar SP, Guler R, Khutlang R, et al. Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 2014; 209: 754–61.

114 Napier RJ, Norris BA, Swimm A, et al. Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog 2015; 11: e1004770.

115 Daley P, Jagenabathan V, John KR, et al. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2015; 15: 528–34.

116 Rahman S, Rehn A, Rahman J, Andersson J, Svensson M, Brighenti S. Pulmonary tuberculosis patients with a vitamin D deficiency demonstrate low local expression of the antimalarial peptide LL-37 but enhanced FoxP3+ regulatory T cells and IgG-secreting cells. Clin Immunol 2015; 156: 85–97.

117 Kaufmann SH, Lange C, Rao M, et al. Progress in tuberculosis vaccination development and host-directed therapies—a state of the art view. Lancet Respir Med 2014; 2: 301–20.

118 Leung J, Suh WK. The CD28-B7 family in anti-tumor immunity: emerging concepts in cancer immunotherapy. Immune Netw 2014; 14: 265–76.

119 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–64.

120 Singh A, Mohan A, Dey AB, Mitra DK. Inhibiting the programmed death-1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis 2013; 208: 603–15.

121 Jurado JO, Alvarez IB, Pasquinelli V, et al. Programmed death (PD)-1/PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 2008; 181: 116–25.

122 Hassan SS, Akram M, King EC, Dockrell HM, Clift JM. PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS One 2015; 10: e0137646.

123 Ngio SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011; 71: 6567–71.

124 Sada-Ovalle I, Chávez-Galán L, Torre-Bouscoulet L, et al. The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. J Immunol 2012; 189: 5896–902.

125 Phillips BL, Mehta S, Alish MH, Selman M, Khader SA, Kauldal D. LAG3 expression in active Mycobacterium tuberculosis infections. Am J Pathol 2015; 185: 820–30.

126 Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat Rev Immunol 2015; 15: 45–56.

127 Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009; 48: 1429–32.

128 Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res 2015; 21: 428–52.
